BiotechTube
Home/Myosin Therapeutics/Patrick R. Griffin
PR

Patrick R. Griffin

Chief Scientific Officer

Myosin Therapeutics

Therapeutic Areas

OncologyNeuroscienceMusculoskeletal

Myosin Therapeutics Pipeline

DrugIndicationPhase
MT-125Glioblastoma (GBM), MGMT unmethylatedPhase 1/2
MT-228Oncology (likely PDAC)Preclinical
MT-110Substance Use Disorder (SUD)Preclinical
MT-134MusculoskeletalPreclinical

Leadership Team at Myosin Therapeutics

CA
Courtney A. Miller
Chief Executive Officer
KS
Karen Smith
Chief Medical Officer
TK
Theodore Kamenecka
Chief Scientific Officer
View full Myosin Therapeutics profile